Neurotech’s ENCELTO Becomes First FDA-Approved Treatment for Macular Telangiectasia Type 2
Neurotech Pharmaceuticals, Inc. has announced that the FDA has approved ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel), a progressive neurodegenerative retinal disease that leads to irreversible vision loss. ENCELTO is the first and only FDA-approved treatment for MacTel and utilizes an innovative encapsulated cell therapy technology to deliver continuous therapeutic doses of ciliary neurotrophic factor (CNTF) to the retina, helping to slow disease progression. The approval was based on results from two Phase III clinical tr...
